AI Summary
The content provided explains a new delivery system for CRISPR gene editing in living animals. Researchers have used two types of antibody fragments to selectively deliver CRISPR-Cas9, guide RNA, and a transgene to T-cells in mice. This technique has the potential to make it easier to create CAR T-cells for cancer therapy in vivo. The goal is to develop a method to target CRISPR-filled delivery vehicles to any cell type, which would eliminate the need for ex vivo cell editing in current gene therapies.
By attaching two kinds of antibody fragments to membrane-derived globules, researchers selectively delivered CRISPR-Cas9, guide RNA and a transgene to T-cells in living mice to create CAR T-cells. While this technique could make it easier to create CAR T-cells in vivo for cancer therapy, the ultimate goal is to selectively target CRISPR-filled ‘enveloped delivery vehicles’ to any type of cell and avoid the ex vivo cell editing now used in current gene therapies.